Sin conexión a internet: se muestra la versión guardada de la página.

Molecular Partner…

CHCHF
← Al Screener

Molecular Partners AG (LSE:0QXX) — Biotechnology: Biological Products (No Diagnostic Substances). Número de bolsas en las que cotizan las acciones de la empresa: 3. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.

Sobre la Empresa

Sitio Web
molecularpartners.com
Sector
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Sede Central
Schlieren-Zurich, Switzerland
Consejero Delegado
Patrick Amstutz
Empleados
134
Acciones en Circulación
38.31 M
Capital Flotante
20.71 M
Capitalización Bursátil
127.56 M CHF
Insiders
8.47%
Inversores Institucionales
43.8%
Industria (SIC)
Biological Products, (No Diagnostic Substances)
Forma Jurídica
MVII
ISIN
US60853G1067
LEI
875500AXMLDAZ4D21744
FCF
−52.0 M CHF
Deuda
?
Resultados y FCF — para los 12 meses hasta 31.12.2025 (el último informe de la empresa).
Descripción

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

anuncio

Bolsas y Tickers

BolsaTickerMonedaPrecioTipo
SW SIX Swiss ExchangeMOLN principalCHF3.33 -0.30%acciones ordinarias
LSE London Stock Exchange0QXX IOBCHF3.39 +0.00%acciones ordinarias
US USA StocksMLLCF OTCUSD4.01 +0.00%acciones ordinarias

Precio en 3 Meses

día alcista día bajistaPasa el cursor / toca un día — precios de apertura, cierre, máximo y mínimo

Principales Accionistas

TitularParticipaciónAccionesFecha del Informe
Old Mission Capital, LLC0.03%11 3472025-06-30
DFA INVESTMENT DIMENSION…0.01%3 9232026-07-31
DFA INVESTMENT DIMENSION…0.01%3 5032026-07-31
American Century ETF Tru…0%122026-08-31